Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma


Cite item

Full Text

Abstract

References

  1. Guidelines on benign prostatic hyperplasia / de la Rosette J., Alivizatos G., Madersbacher S. et al. European Association of Urology.
  2. Jacobsen S. J. et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J. Urol. (Baltimore) 1996; 155: 595-600.
  3. McConnell J. D. et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Engl. J. Med. 1998; 338: 557-563.
  4. Djavan B. et al. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient?s quality of life. Urology 2003; 62 (3, suppl. 1): 6-14.
  5. Levin R. M. et al. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens. Urol. Res. 2000; 28 (3): 201-209.
  6. Hutchison A. et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur. Urol. 2007; 51 (1): 207-215; discus.: 215-216.
  7. Koch E. et al. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med. 2001; 67 (6): 489-500.
  8. Debruyne F. et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur. Urol. 2002; 41 (5): 497-506; discus.: 506-507.
  9. Kaplan S. A. et al. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J. Urol. (Baltimore) 2004; 171 (1): 284-288.
  10. Мазо Е. Б. и др. Опыт длительного применения препарата Простамол Уно у больных доброкачественной гиперплазией предстательной железы. Рус. мед. журн. 2006; 14 (12): 921-924.
  11. Сивков А. В. и др. Морфологические изменения в предстательной железе больных. Урология 2004; 5: 10-16.
  12. Pytel Y. A. et al. Long-term clinical and biologic effects of the lipidosterol extract of Serenoa repens in patients with symptomatic benign prostatic hypeplasia. Advanc. Ther. 2002; 19 (6): 297-306.
  13. Аляев Ю. Г. и др. Пятилетний опыт лечения пермиксоном (Serenoa repens, "Pierre Fabre Medicament") больных гиперплазией простаты. Урология 2002; 1: 23-25.
  14. Аляев Ю. Г., Аполихин О. И., Мазо Е. Б. и др. Первые результаты клинического исследования по изучению эффективности и безопасности приема препарата Простамол® Уно больными с начальными проявлениями гиперплазии простаты. Эффектив. фармакотер. в урол. 2007; 4: 8-11.
  15. Bach D. et al. Long-term drug treatment of benign prostatic hyperplasia. Results of a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomedicine 1996; 3: 105.
  16. Braeckman J. et al. Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia. Therapeutic equivalence between twice and once daily dosage forms. Phytother. Res. 1997; 11: 558.
  17. Nickel J. C. et al. Family Pract. News 1997; August 1: 30.
  18. Fong Y. Curr. Opin. Urol. 2005; 15 (1): 45-48.
  19. Djavan B., Fong Y. et al. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. Wld J. Urol. 2005; 23 (4): 253-256.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies